Corebridge Financial Inc. Cuts Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Corebridge Financial Inc. lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 5.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 41,116 shares of the medical research company's stock after selling 2,601 shares during the period. Corebridge Financial Inc.'s holdings in IQVIA were worth $8,080,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of IQVIA by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company's stock valued at $3,956,087,000 after acquiring an additional 105,504 shares in the last quarter. LPL Financial LLC raised its stake in IQVIA by 1.4% in the 4th quarter. LPL Financial LLC now owns 96,506 shares of the medical research company's stock valued at $18,964,000 after purchasing an additional 1,311 shares during the last quarter. Fox Run Management L.L.C. purchased a new position in IQVIA in the 4th quarter valued at $541,000. KLP Kapitalforvaltning AS acquired a new stake in IQVIA during the 4th quarter worth $12,316,000. Finally, AXQ Capital LP purchased a new stake in shares of IQVIA during the fourth quarter worth $693,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on IQV. UBS Group lowered their price target on shares of IQVIA from $260.00 to $255.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. JPMorgan Chase & Co. lowered their target price on IQVIA from $240.00 to $232.00 and set an "overweight" rating on the stock in a report on Tuesday, February 18th. Barclays cut their price target on IQVIA from $255.00 to $235.00 and set an "overweight" rating for the company in a report on Monday, February 3rd. BTIG Research cut IQVIA from a "buy" rating to a "neutral" rating in a report on Monday, February 3rd. Finally, StockNews.com downgraded IQVIA from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th. Five research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $249.05.

Remove Ads

IQVIA Trading Down 1.1 %

Shares of NYSE IQV traded down $1.90 during trading on Tuesday, reaching $174.41. The stock had a trading volume of 181,194 shares, compared to its average volume of 1,298,658. The business's 50-day moving average price is $192.73 and its 200-day moving average price is $205.61. IQVIA Holdings Inc. has a fifty-two week low of $169.37 and a fifty-two week high of $253.84. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The company has a market cap of $30.75 billion, a P/E ratio of 23.26, a PEG ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.